MedPath

Ergomar

Ergomar Sublingual Tablets, 2 mg

Approved
Approval ID

dac9637f-3326-4f25-b7b9-f9f54b738232

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 25, 2022

Manufacturers
FDA

TerSera Therapeutics, LLC

DUNS: 080226115

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Ergotamine Tartrate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code70720-120
Application NumberANDA087693
Product Classification
M
Marketing Category
C73584
G
Generic Name
Ergotamine Tartrate
Product Specifications
Route of AdministrationORAL
Effective DateDecember 1, 2016
FDA Product Classification

INGREDIENTS (8)

Ergotamine TartrateActive
Quantity: 2 mg in 1 1
Code: MRU5XH3B48
Classification: ACTIB
CrospovidoneInactive
Code: 2S7830E561
Classification: IACT
Microcrystalline CelluloseInactive
Code: OP1R32D61U
Classification: IACT
Saccharin SodiumInactive
Code: SB8ZUX40TY
Classification: IACT
FD&C Blue NO. 1Inactive
Code: H3R47K3TBD
Classification: IACT
Magnesium StearateInactive
Code: 70097M6I30
Classification: IACT
Aluminum OxideInactive
Code: LMI26O6933
Classification: IACT
D&C Yellow NO. 10Inactive
Code: 35SW5USQ3G
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Ergomar - FDA Drug Approval Details